Not logged in...
About USC Norris
FAQ - Trials
Contact Us - Trials
Support USC Norris
» Contact Us
If you are a patient, please contact
Keck Medical Center of USC
Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy.
Open to Accrual
Defintions of terms and FAQ about clinical trials.
Barbara Gitlitz, M.D.
Other Trial Staff:
Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Gina Tse, R.N., Eduardo Mejia, D.M.
to see study documents.
Click here to see trial eligibility criteria and further details at ClinicalTrials.gov
For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or
To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.